Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Net Cash Flow (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Net Cash Flow for 4 consecutive years, with $38.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 279.5% to $38.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 117.63% increase, with the full-year FY2025 number at $10.2 million, up 117.63% from a year prior.
  • Net Cash Flow was $38.2 million for Q4 2025 at Spruce Biosciences, up from -$48.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $49.2 million in Q1 2023 to a low of -$48.9 million in Q3 2025.
  • A 4-year average of $373625.0 and a median of -$571000.0 in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 353.66% in 2023, then tumbled 829.95% in 2024.
  • Spruce Biosciences' Net Cash Flow stood at $2.9 million in 2022, then plummeted by 185.84% to -$2.5 million in 2023, then tumbled by 765.58% to -$21.3 million in 2024, then soared by 279.5% to $38.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Net Cash Flow are $38.2 million (Q4 2025), -$48.9 million (Q3 2025), and $8.5 million (Q2 2025).